Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: Oncogene. 2020 Dec 15;40(5):997–1011. doi: 10.1038/s41388-020-01563-x

Fig. 3.

Fig. 3.

Tam treatment blocked metastasis in ESR1 mutant tumors. A and B. MCF-7 parental and YS1 mutant cells were injected in nude mice supplemented in E2 and randomized to three treatment armsto continue E2 (+E2), E2 removal (-E2) or E2 removal +Tam (-E2+Tam). Time to tumor doubling or halving are shown in A and B respectively using Kaplan-Meier method (P values showed in Supplementary Table 9 and 10). C and D. Number of mice that developed macrometastasis or lung micrometastasis in each treatment arm are shown. Data were analyzed using chi-square and Fisher’s exact test. * P <0.05, ** P <0.01, NS= no significant. E. Immunoblot analysis of primary tumors from MCF-7 YS1 mutant tumors treated with E2 withdrawal (-E2) (N=7) or -E2 +Tam (N=6). F. The frequency of lung micrometastasis were evaluated in WHIM20 PDX models grown in absence of E2 (-E2) or -E2+Tam. Time to tumor doubling was calculated using Kaplan-Meier method and analyzed using Log-rank (Mantel-Cox) Test. P=0.0978. G. After 5 months, mice were harvested and the frequency of lung micrometastasis was analyzed using chi-square and Fisher’s exact test. * P <0.05.